Fatty Liver

The supplied grounding identifies an imbalance in fatty acid metabolism as the core cause of fatty liver. In the literature, hepatic steatosis is linked to excess hepatic fatty acid uptake, increased de novo fatty acid synthesis, reduced fatty acid oxidation, and impaired export of triglyceride in very low-density lipoprotein.

Fatty liver develops when triglyceride accumulation in hepatocytes exceeds the liver's capacity to oxidize or export fat. The literature also links progression beyond simple steatosis to inflammatory and injury pathways involving endoplasmic reticulum stress, signaling networks, adipocytokines, innate immunity, and influences from the gut and adipose tissue.

Obesity is a major risk factor, and the literature also associates fatty liver with insulin resistance and metabolic dysfunction. The supplied grounding additionally highlights body mass index, diet, genetic factors, epigenesis, gastrointestinal microbiome changes, and systemic metabolic abnormalities as relevant risk-related factors.

The supplied grounding supports treatment at the modality and drug-class level rather than specific regimens. It includes drug therapy with agents such as GLP-1 receptor agonists and related metabolic therapies, as well as thyroid hormone receptor beta-targeted therapy; broader management is framed around metabolic risk reduction and disease stratification. The grounding does not support more specific standard-of-care details beyond these categories.